I N T E L L I G E N T T E C H
GE HEALTHCARE TAKES STEP TOWARDS EXPANDING ACCESS TO ADVANCED MOLECULAR IMAGING TECHNOLOGIES
GE HealthCare has announced that StarGuide GX, its new digital 4D CZT SPECT / CT technology, is 510( k) pending with the US Food and Drug Administration( FDA). Building on the system’ s recent CE Mark, this milestone is a step towards expanding access to advanced molecular imaging technologies in the United States and marks a significant moment in molecular imaging’ s evolution – aiming to empower clinicians with a high-performance, general-purpose scanner to help personalise care across a growing range of nuclear medicine applications and tracers, including the acquisition of alpha emitters.
“ We are seeing a meaningful evolution in precision care, driven in large part by the continued growth of theranostic and the integration of imaging and targeted therapies,” said Professor Ken Herrmann, Chair, Department of Nuclear Medicine, University Hospital Essen.“ As new tracers – including the anticipated development of alpha-emitting agents – expand what’ s possible in diagnosis and treatment, it is essential that imaging technology evolves alongside them. Having systems that can accurately
capture, quantify and support these advances will be critical to enabling more personalised care and improving patient outcomes.”
Momentum is growing in nuclear medicine, driven by a developing pipeline of radioligand therapies poised to reshape the field. Increasing clinical and research interest in alpha-emitting isotopes, such as Actinium-225, Lead 212 and others for highly targeted cancer treatment, offer the potential for greater precision by delivering high-energy radiation over short distances to help minimise damage to surrounding healthy tissue. As this pipeline expands, the ability to accurately image and quantify alpha emitters is anticipated to become increasingly important – not only to support therapy planning and dosimetry, but also to monitor treatment response and advance clinical research.
This shift highlights the potential value of imaging technologies like StarGuide GX, which is designed to deliver the sensitivity, flexibility and energy range expected to be important for keeping pace with emerging tracers. Designed for versatility, the system can image across a broad spectrum of energy levels – supporting both general-purpose SPECT imaging and investigational radioligand therapy isotopes – aiming to enable clinicians and researchers to explore new diagnostic and therapeutic pathways while maintaining exceptional image clarity and quantitation critical for treatment planning and monitoring.
“ StarGuide GX reflects the future of nuclear medicine, where flexibility, speed and quantitative accuracy are essential,” said Erez Levy, Executive Director, Molecular Imaging, GE HealthCare.“ It is designed to act as an all-in-one system and support advanced imaging techniques and emerging tracers, aiming to provide a powerful tool for clinicians looking to expand clinical capabilities and deliver personalised care.”
Powered by GE HealthCare’ s patented dual-sided cadmium zinc telluride( CZT) detector technology, StarGuide GX is designed to deliver double volume sensitivity and maintain highresolution imaging, enabling clinicians to capture more information with shorter scan times. The system also incorporates NVIDIA RTX computing to help optimise image reconstruction and accelerate time to results. �
32 www. intelligenthealth. tech